Labcorp sets 5-8% revenue CAGR through 2029, reaffirms FY26 guidance

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Labcorp reaffirms full-year 2026 financial guidance
  • Targets 5% to 8% compound annual revenue growth through 2029
  • Projects 8.5% to 11.5% compound annual adjusted EPS growth
  • Highlights strategic focus on diagnostics, biopharma, and technology
powered bylight_fuzz_icon
50585311

*this image is generated using AI for illustrative purposes only.

Labcorp (NYSE: LH) reaffirmed its full-year 2026 guidance while unveiling a long-term financial outlook through 2029. The global laboratory services provider outlined compound annual revenue growth of 5% to 8% and adjusted earnings per share (EPS) growth of 8.5% to 11.5%.

The company announced these projections ahead of its 2026 Investor Day, scheduled for 9 am ET on Sept. 10, 2026, in Burlington, N.C.

Strategic Growth Priorities

Labcorp stated that its long-term value creation framework is driven by sustainable growth, strong cash flow generation, and disciplined capital deployment. The firm highlighted its differentiated platform, which it claims is powered by science, technology, and global scale.

Management emphasized the company’s position at the intersection of diagnostics, biopharma, science, and technology as a key driver for creating long-term value for customers and shareholders.

What the Numbers Show

The disclosed guidance indicates a targeted acceleration in earnings growth relative to top-line expansion. With adjusted EPS CAGR projected at 8.5% to 11.5% against a revenue CAGR of 5% to 8%, the outlook implies an expected margin expansion or operational leverage over the four-year period through 2029.

Which specific segments within Labcorp's biopharma and diagnostics divisions are expected to drive the projected 8.5% to 11.5% EPS growth?

How does Labcorp plan to achieve margin expansion through operational leverage amidst potential healthcare cost containment pressures?

What role will emerging technologies, such as AI-driven diagnostics or genomic sequencing, play in sustaining the 5% to 8% revenue CAGR through 2029?

like20
dislike

Labcorp settles wiretapping claims with two-year tracking tech ban

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Labcorp settles class action alleging wiretapping law violations in CA and PA
  • Agreement includes a two-year ban on tracking tech like Meta Pixel and Google Analytics
  • Settlement provides only injunctive relief; no monetary damages for class members
  • Class covers users who conducted search queries between May 1, 2021, and April 1, 2026
  • Objections must be postmarked by Nov. 23, 2026
powered bylight_fuzz_icon
50112238

*this image is generated using AI for illustrative purposes only.

Labcorp has agreed to a settlement resolving a class action lawsuit alleging violations of wiretapping laws in California and Pennsylvania. The agreement, announced on Sept. 4, 2026, provides only injunctive relief and does not involve monetary damages for class members.

The plaintiffs alleged that Labcorp facilitated the interception of personally identifiable information through third-party tracking technologies on its website. Labcorp denies all allegations of wrongdoing and liability but agreed to the settlement to resolve the litigation.

Settlement Terms

Under the proposed terms, Labcorp must adhere to the following operational changes for two years:

  • Cease using or enabling certain tracking technologies, including Meta Pixel and Google Analytics, on labcorp.com and its subpages.
  • Conduct annual reviews and prepare compliance reports demonstrating adherence to the prohibition.
  • Maintain a written policy regarding the use of externally developed tracking technologies.
  • Designate a senior employee responsible for overseeing compliance.

Class Definition and Rights

The settlement covers individuals in California and Pennsylvania who conducted search queries on Labcorp's website between May 1, 2021, and April 1, 2026. Search queries include entries into search bars or selections from drop-down menus.

Because the relief is solely injunctive, class members cannot opt out. If approved, members will release claims for injunctive relief but retain rights to seek monetary damages. Objections must be postmarked by Nov. 23, 2026.

What the Numbers Show

The settlement structure isolates the financial impact to legal costs rather than direct payouts to users. By limiting the resolution to injunctive relief, Labcorp avoids immediate cash outflows for class members while accepting long-term operational constraints on its digital analytics infrastructure.

How might the prohibition of Meta Pixel and Google Analytics impact Labcorp's digital marketing ROI and customer acquisition strategies over the next two years?

Will this settlement set a legal precedent that encourages similar injunctive-only class actions against other healthcare providers using third-party tracking tools?

What are the potential long-term operational costs for Labcorp in maintaining the new compliance infrastructure and annual reporting requirements?

like20
dislike

More News on Labcorp Holdings Inc